Alaunos Therapeutics, Inc. — Form 8-K Summary
Reporting date: October 13, 2026. This is a transaction-focused current report, not a periodic financial-results filing.
Business context and transaction
Alaunos completed its business combination with Velaris Therapeutics on October 13, 2026. Velaris merged into a wholly owned Alaunos subsidiary. The filing describes Velaris’s research programs and agreements, but provides no revenue, earnings, operating cash flow, or balance-sheet results for either company.
Financial and capital matters
| Item | Disclosure |
|---|---|
| Financing | Alaunos agreed to sell common and Series C preferred securities for approximately $350 million gross. The financing closing was expected October 14, 2026, subject to customary conditions; the filing does not confirm completion or state net proceeds. |
| Use of proceeds | Intended primarily for research and development of Velaris programs, plus working capital and general corporate purposes. Contractual restrictions limit use for the legacy business, stock repurchases, and certain insider or affiliate debt repayments without Lead Investor consent. |
| Merger consideration and potential dilution | Former Velaris stockholders received 105,286 Series B and 33,054 Series C preferred shares, each convertible into 1,000 common shares, subject to conditions. Financing investors were also to receive 687,789 common shares and 243,063 Series C preferred shares, with each preferred share convertible into 1,000 common shares. |
| Existing preferred stock | Following stockholder approval of the conversion proposal, Alaunos will repurchase the existing Series A-1 and A-2 preferred securities, or related common shares, for approximately $1.6 million if approval occurs before February 2027. |
| Other financial metrics | The filing does not provide clear values for revenue, profit, margins, cash flow, cash balance, debt, or liquidity apart from the transaction disclosures above. |
Material changes and governance
- The company issued non-voting convertible preferred securities in connection with the merger and planned financing. Conversion requires stockholder approval of the conversion proposal and an authorized-share increase, and is subject to beneficial-ownership limits.
- Stockholders will also be asked to approve a company name change to Velaris Therapeutics, redomestication, a reverse stock split at a ratio to be set, and a new equity incentive plan. Alaunos intends to file a proxy statement.
- Peter Harwin joined the board at closing. Three existing directors’ resignations become effective only if stockholders approve the conversion proposal. Following that approval, Lead Investor designees and a Velaris designee are expected to constitute four of five directors.
- The company agreed to operate Velaris’s programs under an agreed development plan and budget, generally without material deviation absent Lead Investor consent, until specified conversion, time, or consent conditions are met.
Outlook, risks, contingencies, and unusual items
- The financing remained subject to closing conditions as of the report. Stockholder approvals are also necessary for the planned preferred-stock conversions and related charter changes. If the required approvals are not obtained, holders may, beginning six months after issuance, require cash settlement of conversions based on the defined fair value.
- Paragon Laboratories will conduct research on fusion-protein programs under an option arrangement. Future licenses may require milestone payments and single-digit royalties. Two warrants, each for shares equal to 1% of fully diluted shares, are scheduled for grant at 120 days and 12 months after closing.
- Paragon may have a time-limited right to terminate a license and recover related rights if, among other events, stockholders’ equity does not exceed $200 million at the end of the second full fiscal quarter after closing, required reporting is late, or freely tradeable shares are not delivered after warrant exercise. The filing does not establish whether these conditions will be met.
- Company and Velaris executives may earn retention bonuses of $206,250 and $90,000, respectively, subject to specified service and other conditions. Related options cover 50,000 and 10,000 common shares at $1.4357 per share.
- The filing identifies forward-looking uncertainties around financing completion, stockholder approval, program development, registration of resale shares, the preferred-stock repurchase, and Paragon’s rights. It provides no operating forecast or quantified clinical or commercial outlook.
Most important facts for investors to verify
- Whether the approximately $350 million financing closed, and the net proceeds and resulting cash runway.
- The proxy proposals, voting results, conversion mechanics, authorized-share increase, reverse-split terms, and ultimate dilution.
- The company’s post-transaction financial position, including cash, debt, stockholders’ equity, and spending plans; these are not quantified in this 8-K.
- Whether the conditional $1.6 million preferred-stock repurchase occurs and how governance changes after any stockholder approval.
- The detailed development plan, Paragon agreement terms and potential reversion triggers, and any subsequent updates on Velaris program development.